Get the Stockscreener App
2.12
1.85%
-0.04
After Hours:
2.12
Alector Inc stock is traded at $2.12, with a volume of 814.46K.
It is down -1.85% in the last 24 hours and down -17.51% over the past month.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
See More
Previous Close:
$2.16
Open:
$2.13
24h Volume:
814.46K
Relative Volume:
1.14
Market Cap:
$235.37M
Revenue:
$21.05M
Net Income/Loss:
$-142.93M
P/E Ratio:
-1.5257
EPS:
-1.3895
Net Cash Flow:
$-184.07M
1W Performance:
+3.41%
1M Performance:
-17.51%
6M Performance:
+66.93%
1Y Performance:
+73.77%
1-Day Range:
$2.045
$2.18
1-Week Range:
$2.03
$2.37
52-Week Range:
$1.09
$3.3999
Alector Inc Stock (ALEC) Company Profile
Name
Alector Inc
Sector
Industry
Phone
415-231-5660
Address
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Compare ALEC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
2.12 | 239.81M | 21.05M | -142.93M | -184.07M | -1.3895 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alector Inc Stock (ALEC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-10-26 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-22-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-22-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-22-25 | Downgrade | Mizuho | Outperform → Neutral |
| Oct-22-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-28-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-17-24 | Downgrade | Mizuho | Outperform → Neutral |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-04-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-29-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-26-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-14-23 | Upgrade | Stifel | Hold → Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Sep-25-23 | Initiated | Goldman | Sell |
| Sep-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-13-22 | Initiated | Goldman | Sell |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Sep-27-21 | Initiated | William Blair | Outperform |
| Jan-15-21 | Resumed | BofA Securities | Buy |
| Jun-24-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-19-20 | Initiated | Stifel | Buy |
| Nov-21-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | Barclays | Overweight |
| Mar-04-19 | Initiated | BofA/Merrill | Buy |
| Mar-04-19 | Initiated | Morgan Stanley | Overweight |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
View All
Alector Inc Stock (ALEC) Latest News
Polaris entities hold 4.85M ALEC shares (ALEC) — Amendment No.7 - Stock Titan
Alector (ALEC)'s technical outlook is bright after key golden cross - MSN
TradingKey - TradingKey
Alector Establishes $125 Million At-the-Market Offering - The Globe and Mail
Myles Minter Reiterates Hold on Alector as Late-Stage Trial Failures Trigger Pipeline Reset but Next-Gen Brain Carrier Platform Offers Long-Term Optionality - TipRanks
Alector (ALEC) Reports Q1 Revenue Shortfall Amidst Strategic Dev - GuruFocus
Alector, Inc. Announces $125 Million Common Stock Sales Agreement with TD Securities (USA) LLC - Minichart
Alector: Q1 Earnings Snapshot - theheraldreview.com
Alector posts first quarter 2026 financial results amid new business updates - Traders Union
Alector : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Alector (NASDAQ: ALEC) establishes $125M stock ATM facility - Stock Titan
Alector (NASDAQ: ALEC) files $125M ATM offering with TD Cowen - Stock Titan
Alector (NASDAQ: ALEC) narrows Q1 2026 loss as it refocuses pipeline - Stock Titan
Alector Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Alector | 10-Q: Q1 2026 Earnings Report - Moomoo
Alector | 8-K: Alector Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Alector (NASDAQ: ALEC) Q1 2026 results, trial halt and ABC focus - Stock Titan
BRIEF-Alector Q1 Basic EPS USD -0.21 - TradingView
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
MSN Money - MSN
Transcript : Alector, Inc.Special Call - marketscreener.com
Alector Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Five-Way Obesity Drug Shows Effectiveness in Mice; Alector Stops Alzheimer’s Trial - geneonline.com
Franklin Lexington Private Markets Fund's Alector Inc(ALEC) Holding History - GuruFocus
Morgan Stanley raises Alector stock price target on pipeline focus By Investing.com - Investing.com Australia
Morgan Stanley raises Alector stock price target on pipeline focus - Investing.com
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Alector (ALEC) - The Globe and Mail
Failure of GSK-partnered Alzheimer’s drug a fresh setback for Alector - The Pharma Letter
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC) and Alector (ALEC) - The Globe and Mail
Peninsula biotech Alector loses another Alzheimer's battle, shifts to earlier-stage programs - The Business Journals
Alector drops GSK-partnered Alzheimer’s drug (ALEC:NASDAQ) - Seeking Alpha
How The Alector (ALEC) Narrative Is Shifting Toward BBB Shuttle Programs And Execution Risk - Yahoo Finance
GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints - BioSpace
5AM Venture Management, LLC's Alector Inc(ALEC) Holding History - GuruFocus
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis - The Manila Times
Biopharmaceutical company Alector Inc. announced that it will discontinue its Phase II PROGRESS-AD clinical trial of its candidate drug Nivisnebart (development code AL101/GSK4527226) for the treatment of early-stage Alzheimer's disease. - Bitget
Alector to discontinue phase 2 trial of nivisnebart - marketscreener.com
Alector to Discontinue Phase 2 PROGRESS-AD Trial of - GlobeNewswire
Alzheimer’s drug study stops early after review finds low odds of success - Stock Titan
Cantor Fitzgerald upgrades Alector (ALEC) - MSN
Alector (NASDAQ: ALEC) sets 2026 virtual meeting on directors, auditor and say-on-pay - Stock Titan
Alector | ARS: Annual Report to Security Holders - Moomoo
BlackRock (ALEC) discloses 5.2% ownership of Alector common stock - Stock Titan
Alector gains as Cantor Fitzgerald upgrades on brain carrier platform - MSN
Alector | SCHEDULE 13G: Others - Moomoo
Alector (ALEC) Price Target Decreased by 42.61% to 2.24 - MSN
Alector Inc Stock (ALEC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):